EichorEICHOR
Location: Quilmes Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Quilmes

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Phase 3 · Instituto de Investigaciones Clinicas Quilmes · Takeda · NCT06671496LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2 · CER medical Institute · Eli Lilly and Company · NCT07415044A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · CER medical Institute · Pfizer · NCT05895786A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate
Phase 3 · Teva Investigational Site 20146 · Teva Branded Pharmaceutical Products R&D LLC · NCT06664619Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIR
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06133972Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Dee
Phase 3 · Anthos Investigative Site 1417 · Anthos Therapeutics, Inc. · NCT05712200A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Act
Phase 3 · Sl0044 60003 · UCB Biopharma SRL · NCT06617325A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Phase 2 · Instituto de Investigaciones Clinicas Quilmes · Boehringer Ingelheim · NCT07409181A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD
Phase 3 · Centro Respiratorio Quilmes · Hoffmann-La Roche · NCT05878769The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Phase 3 · Centro Respiratorio de Quilmes · Boehringer Ingelheim · NCT06872892Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
Phase 2 · Centro Respiratorio Quilmes_Site n. 032007 · Chiesi Farmaceutici S.p.A. · NCT07301736A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With
Phase 3 · Research Site · AstraZeneca · NCT06023589A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Pr
Phase 3 · Centro Respiratorio de Quilmes · Boehringer Ingelheim · NCT06238622A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Phase 3 · Instituto de Investigaciones Clinicas Quilmes ( Site 1903) · Merck Sharp & Dohme LLC · NCT07218029A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Phase 3 · Instituto de Investigaciones Clínicas de Quilmes · Boehringer Ingelheim · NCT07497087A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Phase 2/Phase 3 · EyeBiotech Ltd. · NCT07440225A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standa
Phase 3 · Research Site · AstraZeneca · NCT06455449Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Phase 3 · Instuto de Investigacion Clinicas Quilmes · Gossamer Bio USA, Inc. · NCT06274801A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Ery
Phase 4 · GSK Investigational Site · GlaxoSmithKline · NCT06411249A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a
Phase 3 · Instituto Medico CER · Boehringer Ingelheim · NCT06935370A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Phase 3 · Instituto de Investigaciones Clínicas de Quilmes · Boehringer Ingelheim · NCT06424288A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D
Phase 3 · Research Site · AstraZeneca · NCT06878261Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Phase 3 · Instituto De Investigaciones Clinicas Quilmes · Eli Lilly and Company · NCT07157774A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Phase 2 · CER Instituto Medico · Eli Lilly and Company · NCT06598943A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Phase 3 · Instituto CER S.A. · Amgen · NCT06747949A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Phase 3 · Cer Instituto Medico · Janssen Research & Development, LLC · NCT07438496Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T
Phase 3 · GSK Investigational Site · GlaxoSmithKline · NCT06961214A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderate
Phase 3 · Instituto Medico CER · Hoffmann-La Roche · NCT06819891A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants
Phase 3 · Instituto Medico CER · Hoffmann-La Roche · NCT06588855A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and
Phase 3 · CER medical Institute · Eli Lilly and Company · NCT07241390
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.